Navigation Links
Amgen And Servier Announce Product Collaboration
Date:7/9/2013

or heart failure and angina. Ivabradine, an If inhibitor, offers a novel alternative approach for patients with elevated heart rates. We value Servier's extensive experience in cardiovascular disease and look forward to working with them as Amgen continues to build our presence in this area."

"Servier is very pleased to establish a collaboration with Amgen, a leading biotechnology company with a unique track record of bringing innovative medicines to patients. This is a clear recognition of the medical value of ivabradine, one of our major cardiovascular innovations, which could also benefit U.S. patients," said Jean-Philippe Seta, M.D., chief executive officer at Servier.

"Ivabradine is a first-in-class innovative drug for the treatment of heart failure and angina. The clinical benefit and safety profile are supported by the results of clinical studies performed or being performed in more than 40,000 patients. I strongly believe that Servier's expertise in heart failure will complement Amgen's efforts in making omecamtiv mecarbil, a very innovative and complementary approach to treating heart failure, available to patients in Europe," said Emmanuel Canet, M.D., Ph.D., head of Research and Development at Servier.

Ivabradine is an If inhibitor approved by the European Medicines Agency in 2005 for the symptomatic treatment of stable angina and in 2012 for chronic heart failure, as well as approved in more than 100 other countries, excluding the U.S. Omecamtiv mecarbil activates cardiac muscle contractility and operates to strengthen heart function in patients with systolic dysfunction. Omecamtiv mecarbil is in Phase 2 studies and is being developed under a collaboration between Cytokinetics and Amgen.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen
'/>"/>

SOURCE Amgen; Servier
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
2. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
3. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
4. Amgen Announces 2013 Second Quarter Dividend
5. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
6. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
7. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
8. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
9. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
10. Amgen Announces 2012 Third Quarter Dividend
11. Amgen to Present at the Leerink Swann Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... call and webcast to begin after markets close at 2:00 p.m. PT ... ... Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- ... the period ended,September 27, 2008 after the market closes on Monday, October ...
... Oct. 15 PURE Bioscience (Nasdaq:,PURE), creators of ... revenues for the fiscal year ended July 31, ... with $336,400 in the,prior fiscal year. The Company ... or $(0.24) per share, compared with a loss ...
... Agency Expanding Industry Connections, MOUNTAINSIDE, N.J., Oct. ... medical education company,today announced the hiring of Todd ... leverage his experience in medical education and,publishing as ... L&M, he,served as Manager of Publication Sales at ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... changes, might in fact be driven by a simple and ... range of specieshappen to share, according to new research. ... suggests that knowledge of a species, genes and how ... could be used to determine a predictable evolutionary pattern ...
... University of South Florida researchers have identified a genetic ... understanding and preventing a condition of aging that affects ... life. In a nine-year study that was a ... Research and the National Technical Institute for the Deaf ...
... 2012Targeted T-cells can seek out and destroy tumor cells ... that take advantage of this T-cell response are described ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Gene Therapy website at http://www.liebertpub.com/hum . ...
Cached Biology News:Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 2Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 3Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 4Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 5USF researchers identify gene mutation linked to old age hearing loss 2New anti-tumor cell therapy strategies are more effective 2
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
Biology Products: